FocalTherics (FOCL) – What Are Investment Firms Saying About This Stock?

FocalTherics (NASDAQ:FOCL) has been assigned a consensus recommendation of “Hold” from the five brokerages that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $7.75.

A number of research analysts have commented on the company. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of FocalTherics in a research note on Tuesday, August 25th. Wall Street Zen cut FocalTherics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Mizuho set a $15.00 price objective on FocalTherics and gave the stock an “outperform” rating in a report on Friday, July 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of FocalTherics in a research report on Monday, August 17th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $4.00 target price on shares of FocalTherics in a research note on Friday, August 14th.

FocalTherics Stock Performance

NASDAQ:FOCL opened at $4.12 on Wednesday. FocalTherics has a twelve month low of $1.75 and a twelve month high of $6.40. The firm’s 50-day simple moving average is $4.25. The company has a market cap of $154.62 million, a price-to-earnings ratio of -4.00 and a beta of -0.06.

FocalTherics (NASDAQ:FOCL) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.19). The business had revenue of $13.20 million during the quarter. As a group, equities analysts forecast that FocalTherics will post -0.82 earnings per share for the current year.

Insider Buying and Selling at FocalTherics

In related news, CEO Ryan Rhodes acquired 21,000 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were bought at an average price of $4.75 per share, for a total transaction of $99,750.00. Following the acquisition, the chief executive officer owned 626,649 shares in the company, valued at $2,976,582.75. This trade represents a 3.47% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Lance Willsey purchased 50,000 shares of the business’s stock in a transaction on Friday, August 14th. The stock was purchased at an average cost of $4.75 per share, with a total value of $237,500.00. Following the acquisition, the director owned 1,291,780 shares in the company, valued at approximately $6,135,955. This represents a 4.03% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired 116,000 shares of company stock worth $551,000 in the last ninety days. 10.10% of the stock is owned by insiders.

Institutional Investors Weigh In On FocalTherics

An institutional investor recently bought a new stake in FocalTherics stock. Lido Advisors LLC purchased a new stake in FocalTherics (NASDAQ:FOCL) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 10,654 shares of the company’s stock, valued at approximately $40,000. Institutional investors own 62.74% of the company’s stock.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.